
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Researchers working to develop a new HIV prevention tool for the world's women had their hopes shattered when data from a final Phase III human trial of the vaginal microbicide gel Carraguard showed it failed to prevent HIV infections among the more than 6,200 women studied. HIV incidence was only slightly lower among the women using the gel than among those given a placebo. And women used the compound less than half the time they had sex, a rate far lower than expected. 'Even a highly efficacious coitally dependent product will have insufficient effectiveness in real-life settings,' the researchers disappointedly wrote in The Lancet.
From our Sponsors
Most Popular
Plus: Featured Video